Sherlock Biosciences

Last updated

Sherlock Biosciences was a biotechnology company based in Cambridge, Massachusetts that developed diagnostic tests using CRISPR-Cas13. The company was founded in 2019 [1] by Feng Zhang, Jim Collins, Omar Abudayyeh, and Jonathan Gootenberg of the Broad Institute and MIT. [2]

Contents

Cas13 was discovered by Zhang and Eugene Koonin using computational methods, then further characterized by Jennifer Doudna's team at the University of California, Berkeley. In 2020, both Sherlock Biosciences and Mammoth Biosciences from Doudna's lab at UC Berkeley used their similar CRISPR technologies to develop tests for COVID-19. [3] [4]

In 2021, Sherlock Biosciences and The Forsyth Institute announced a strategic partnership focusing on the development of products related to the “detection of human biomarkers in oral cavity and other oral health applications." [5]

In December 2024, Sherlock Biosciences was acquired by OraSure Technologies. [6]

See also

References

  1. ↑ "Sherlock Biosciences". Craft.co. Retrieved 2021-05-27.
  2. ↑ Kincaid, Ellie. "With Launch Of New CRISPR Company, Competition Extends To Diagnostics". Forbes. Retrieved 2022-04-14.
  3. ↑ "SHERLOCK-based one-step test provides rapid and sensitive Covid-19 detection". MIT News | Massachusetts Institute of Technology. 5 May 2020. Retrieved 2022-04-14.
  4. ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 427–433. ISBN   978-1-9821-1585-2.
  5. ↑ "Forsyth Institute and Sherlock Biosciences partner to advance research and technology of human biomarkers in the oral cavity".
  6. ↑ "OraSure Technologies Acquires Sherlock Biosciences".


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.